Fig. 6. SOCS-2 mRNA expression in patients with CML in BC responding to STI571 therapy. / Northern blots of RNA from 5 patients with CML in myeloid BC before and during STI571 therapy, probed with SOCS-2 andβ-actin. The numbers below the blots refer to the densitometric calculation of SOCS-2 levels, normalized toβ-actin. For interindividual comparison of samples, levels before therapy were defined as being 1, and levels under therapy were compared with that value.
Fig. 6.

SOCS-2 mRNA expression in patients with CML in BC responding to STI571 therapy.

Northern blots of RNA from 5 patients with CML in myeloid BC before and during STI571 therapy, probed with SOCS-2 andβ-actin. The numbers below the blots refer to the densitometric calculation of SOCS-2 levels, normalized toβ-actin. For interindividual comparison of samples, levels before therapy were defined as being 1, and levels under therapy were compared with that value.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal